comprehensive -WSS

comprehensive

author：comprehensive 2025-09-28 23:29:55 - browse：25633

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： The Readout: Lenmeldy, GLP

focus

hotspot

explore

WSS

Readout Newsletter: Merck, Vertex, and Viking updates

Indictment alleges Trump's ex

Vertex Pharmaceuticals may move headquarters in Boston

Illumina slashes 2023 revenue projections yet again

Covid vaccine financial winners and losers, from Pfizer to Novavax

Health AI: on the border between health care and tech

focus

comprehensive

hotspot

Psychedelics group wrestles with new pharma identity

There's no autism epidemic. It's an autism diagnosis epidemic

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Mark Cuban is blaming the wrong people for high drug costs

23andMe had bad news about my health. I wish a person had delivered it

Mark Cuban is blaming the wrong people for high drug costs

What does generative AI mean for health care? We asked experts

Hospitals are dialing back on venture capital investing

Moonlake's readout produced a cash windfall. Risks remain

Patient advocates debate FDA's accelerated approval process

knowledge

Scientists boost immune system in aging mice by making it youthful

States should stop sabotaging methadone treatment reform

Judge sides with young activists in first

Dozens dead from Maui wildfires: What we know about the victims

Mark Cuban is blaming the wrong people for high drug costs

Eliminate the waiting period for sterilization covered by Medicaid

focus

hotspot

explore

focus